We have one of the leading pediatric brain tumor programs in the country, and we follow more than 750 children and young adults with brain tumors each year. Our program features:
- Six pediatric brain tumor physicians and researchers, making us one of the largest single-center pediatric groups assembled for this disease
- Innovative treatments for brain tumors through NIH-sponsored clinical trials, providing the most cutting-edge treatments for brain tumors through the COG Phase I Consortium and other multicenter sponsored trials.
- Membership in the Department of Defense Neurofibromatosis Clinical Trials Consortium, offering innovative clinical trials specifically for patients with neurofibromatosis (Type I and Type II).
- Member of the prestigious PBTC—one of 11 centers nationwide.
- Advanced imaging and neurosurgery capabilities, such as MRI software and techniques, an intraoperative MRI system, positron emission tomography (PET) scanning, Gamma Knife technology, and stereotactic radiosurgery and radiotherapy.
- One of only two institutions in the country offering a first-in-pediatrics clinical trial using Indoximod, an inhibitor of an immune “checkpoint” pathway used to treat pediatric patients with refractory malignant brain tumors.
- In collaboration with Georgia Tech, our team is developing nanoparticles for drug delivery across the blood-brain barrier to specifically target pediatric brain tumors.
Click the link for more information on our Neuro-Oncology Program and research.
Our neuro-oncology team:
- Dolly Aguilera, MD
- Robert Castellino, MD
- Anna Janss, MD, PhD, Clinical Director
- Anna Kenney, PhD
- Tobey MacDonald, MD, Program Medical Director
- Claire Mazewski, MD